The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc.

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001. An increasingly popular option among retail and institutional investors, ...

Hatteras Venture Partners has secured over $200 million across a pair of funds that are set to benefit up-and-coming biotechs ...

Older women with genomically high-risk hormone receptor (HR)-positive breast cancer did not benefit from adjuvant ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the ...

From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio ...

Dr Hope Rugo explores how evolving endocrine strategies and targeted therapies are enhancing outcomes in hormone ...

Rising hopes of an interest-rate cut in September pushed US stocks higher on Wednesday, with the S&P 500 and Nasdaq both ...

During a live event, Mar discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.

Major indices were in the green early on Wednesday, with the S&P 500 and Nasdaq Composite building on yesterday's ...

DelveInsight's“ Triple Negative Breast Cancer Pipeline Insight 2025” report provides comprehensive insights about 165+ ...